Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452961 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HTTCYP51A1AVPR1AKMT2A | |
| SCHEMBL5454454 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HTTCYP51A1AVPR1AKMT2A | |
| SCHEMBL5451904 | 0.91 | AVPR1A (0.42) | CYP51A1AVPR1AKMT2ACCR1MC4R | |
| SCHEMBL5452002 | 0.91 | AVPR1A (0.42) | CYP51A1AVPR1AKMT2ACCR1MC4R | |
| SCHEMBL5451899 | 0.91 | AVPR1A (0.42) | CYP51A1AVPR1AKMT2ACCR1MC4R | |
| SCHEMBL5465491 | 0.87 | MC4R (0.40) | ALDH1A1HTTCYP51A1AVPR1AKMT2A | |
| SCHEMBL5458884 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KMT2AMC4RPOLBTRPV1 | |
| SCHEMBL5451845 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KMT2AMC4RPOLBTRPV1 | |
| SCHEMBL5451847 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KMT2AMC4RPOLBTRPV1 | |
| SCHEMBL5456597 | 0.86 | AVPR1A (0.47) | CYP51A1AVPR1AMC4RTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | claimed |
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MC4R, MC5R, TAAR5 | ALDH1A1 344/4885HTT 2683/4885CYP51A1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.